Table 6.
Muropeptide abbreviations
| Monomers | |
| M2, | Dipeptide |
| M3, | Tripeptide |
| M4, | Tetrapeptide |
| M5, | Pentapeptide |
| M4G, | Tetrapeptide(glycine end) |
| M3KR, | Tripeptide Lppa |
| Dimers | |
| D43, | Tetrapeptide–tripeptide |
| D44, | Tetrapeptide–tetrapeptide |
| D45, | Tetrapeptide–pentapeptide |
| D4G3Dap, | Tetrapeptide(glycine end)–tripeptide (Dap–Dap)b |
| D33Dap, | Tripeptide–tripeptide (Dap–Dap) |
| D43Dap, | Tetrapeptide–tripeptide (Dap–Dap) |
| D44G, | Tetrapeptide–tetrapeptide(glycine end) |
| D4G5, | Tetrapeptide(glycine end)–pentapeptide |
| D33KRDap, | Tripeptide–tripeptide Lpp (Dap–Dap) |
| D43KR, | Tetrapeptide–tripeptide Lpp |
| Trimers | |
| T444 | Tetrapeptide–tetrapeptide–tetrapeptide |
| T443 | Tetrapeptide–tetrapeptide–tripeptide |
| T443Dap | Tetrapeptide–tetrapeptide–tripeptide (Dap–Dap) |
| Anhydro muropeptide compounds b | |
| A1, D33KRA | Dimer tripeptide–tripeptide Lpp ahn |
| A2, T444A | Trimer tetrapeptide–tetrapeptide–tetrapeptide anh |
| A3, T443A | Trimer tetrapeptide–tetrapeptide–tripeptide anh |
| A4, T443DapA | Trimer tetrapeptide–tetrapeptide–tripeptide (Dap–Dap) anh |
| A5, D44A | Dimer tetrapeptide–tetrapeptide-anh |
| A6, D43A | Dimer tetrapeptide–tripeptide anh |
| A7, D43DapA | Dimer tetrapeptide–tripeptide (Dap–Dap) anh |
| A8, M4A | Monomer tetrapeptide anh |
| A9, M3A | Monomer tripeptide anh |
a
Lpp, muropeptide with two amino acid residues (“KR” = Lys–Arg) linked to DAP, which represent the remnant of Braun's lipoprotein that was removed during sample processing; Dap–Dap, peptide crosslink formed between two diaminopimelic acids in side chains.
b
Anhydro compounds (“anh”) are muropeptides containing 1,6-anhydromuramic acid, in which the reducing end of the muramic acid moiety is blocked.